{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-Cells&page=2", "query": { "intervention": "T-Cells", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-Cells&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-15T12:26:36.810Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00016055", "title": "Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "lymphokine-activated killer cells", "type": "BIOLOGICAL" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "St. Luke's Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016055" }, { "nct_id": "NCT00005606", "title": "Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" }, { "name": "autologous Epstein-Barr virus-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "2000-02", "completion_date": "2003-09", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005606" }, { "nct_id": "NCT03653338", "title": "T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Anemia", "Beta-thalassemia Major", "Diamond-blackfan Anemia" ], "interventions": [ { "name": "CD3/CD19 depleted leukocytes", "type": "BIOLOGICAL" }, { "name": "CD45RA depleted leukocytes", "type": "BIOLOGICAL" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Paul Szabolcs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "5 Years to 40 Years" }, "enrollment_count": 5, "start_date": "2018-08-02", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03653338" }, { "nct_id": "NCT00001676", "title": "Cyclophosphamide and Fludarabine to Treat Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glomerulonephritis", "Lupus Nephritis", "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "SQ Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "1998-01", "completion_date": "2002-11", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001676" }, { "nct_id": "NCT00434850", "title": "Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Allogeneic Pancreatic Islet Cells", "type": "BIOLOGICAL" }, { "name": "Deoxyspergualin", "type": "DRUG" }, { "name": "Antithymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Daclizumab or basiliximab", "type": "BIOLOGICAL" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2006-10", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2016-03-16", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00434850" }, { "nct_id": "NCT00132691", "title": "Multicenter Uveitis Steroid Treatment (MUST) Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Uveitis" ], "interventions": [ { "name": "fluocinolone acetonide intraocular implant", "type": "DRUG" }, { "name": "oral corticosteroid with immunosuppressive agents as needed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "JHSPH Center for Clinical Trials", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 255, "start_date": "2005-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2016-11-25", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 21, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00132691" }, { "nct_id": "NCT03907527", "title": "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Refractory Fallopian Tube Carcinoma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC V8", "Stage III Ovarian Cancer AJCC V8", "Stage III Primary Peritoneal Cancer AJCC V8", "Stage IIIA Fallopian Tube Cancer AJCC V8", "Stage IIIA Ovarian Cancer AJCC V8", "Stage IIIA Primary Peritoneal Cancer AJCC V8", "Stage IIIA1 Fallopian Tube Cancer AJCC V8", "Stage IIIA1 Ovarian Cancer AJCC V8", "Stage IIIA2 Fallopian Tube Cancer AJCC V8", "Stage IIIA2 Ovarian Cancer AJCC V8", "Stage IIIB Fallopian Tube Cancer AJCC V8", "Stage IIIB Ovarian Cancer AJCC V8", "Stage IIIB Primary Peritoneal Cancer AJCC V8", "Stage IIIC Fallopian Tube Cancer AJCC V8", "Stage IIIC Ovarian Cancer AJCC V8", "Stage IIIC Primary Peritoneal Cancer AJCC V8", "Stage IV Fallopian Tube Cancer AJCC V8", "Stage IV Ovarian Cancer AJCC V8", "Stage IV Primary Peritoneal Cancer AJCC V8", "Stage IVA Fallopian Tube Cancer AJCC V8", "Stage IVA Ovarian Cancer AJCC V8", "Stage IVA Primary Peritoneal Cancer AJCC V8", "Stage IVB Fallopian Tube Cancer AJCC V8", "Stage IVB Ovarian Cancer AJCC V8", "Stage IVB Primary Peritoneal Cancer AJCC V8" ], "interventions": [ { "name": "PRGN-3005 UltraCAR-T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Precigen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 71, "start_date": "2019-04-30", "completion_date": "2028-11-15", "has_results": false, "last_update_posted_date": "2024-11-08", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Seattle, Washington", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907527" }, { "nct_id": "NCT05473910", "title": "A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "MDS" ], "interventions": [ { "name": "SOC + TSC-101", "type": "DRUG" }, { "name": "Control", "type": "OTHER" }, { "name": "SOC + TSC-100", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "TScan Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 310, "start_date": "2022-11-01", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 21, "location_summary": "Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05473910" }, { "nct_id": "NCT01316146", "title": "Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Hodgkin's Lymphoma" ], "interventions": [ { "name": "CAR.CD30 T cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2011-10-03", "completion_date": "2022-05-04", "has_results": false, "last_update_posted_date": "2023-03-22", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 3, "location_summary": "Chapel Hill, North Carolina • Houston, Texas", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01316146" }, { "nct_id": "NCT01675141", "title": "Lenalidomide Maintenance Therapy for Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 11, "start_date": "2012-08-20", "completion_date": "2017-03-10", "has_results": true, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-09-15T12:26:36.810Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01675141" } ] }